Posting Date: December 15, 2020

Closing Date: December 25, 2020 3:30 p.m. ET

Reference Number: 21-011604

To: NCI Bid Board

From: Tanya Alfred
NCI CCR P-ARC
Tanya.alfred@nih.gov

Subject: NCI Bid Board Posting – Service Agreement

The Surgery Branch (SB) of the National Cancer Institute (NCI) is a combined laboratory and clinical research unit devoted to the development of innovative cancer immunotherapies and their translation to the treatment of patients with cancer. Efforts run the gamut from basic studies of cancer immunology to the conduct of clinical immunotherapy trials for patients with metastatic cancer. The Surgery Branch was responsible for the development of interleukin-2 (IL-2), the first effective immunotherapy in humans, the development of cell transfer immunotherapies for melanoma and other solid cancers, the first insertion of foreign genes into humans and the first development of effective human cancer immunotherapies based on the genetic engineering of autologous lymphocytes with genes encoding anti-tumor T cell receptors or chimeric antigen receptors.

The SB seeks to procure a Service Agreement for ICELL8.

The National Cancer Institute plans to purchase a Service Agreements for ICELL8 from Takara Bio USA, Inc. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 3:30 PM on December 25, 2020 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

This acquisition is for a service contract for the ICELL8cx instrument in the genomics facility in the Surgery Branch at NCI. We routinely use this instrument for the dispense of single T-cells into a nanowell chip followed by the dispense of cDNA synthesis reagents. We then generate single-cell cDNA libraries followed by single-cell TCR sequencing libraries from these dispensed cells. Sequencing results are used to identify tumor reactive T cells from patients enrolled in clinical trials run by Surgery Branch. The requested service contract will enable proper maintenance of the system and allow for any necessary repair work in a timely manner which is critical for part of the mission of the Surgery Branch.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request